{"pmid":32388171,"title":"SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome.","text":["SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome.","Eur J Cancer","Di Giacomo, Anna M","Gambale, Elisabetta","Monterisi, Santa","Valente, Monica","Maio, Michele","32388171"],"journal":"Eur J Cancer","authors":["Di Giacomo, Anna M","Gambale, Elisabetta","Monterisi, Santa","Valente, Monica","Maio, Michele"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388171","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ejca.2020.04.026","topics":["Case Report"],"weight":1,"_version_":1666428892731146240,"score":9.490897,"similar":[{"pmid":32439211,"title":"Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?","text":["Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?","Lung Cancer","Di Noia, Vincenzo","D'Aveni, Alessandro","Squadroni, Michela","Beretta, Giordano Domenico","Ceresoli, Giovanni Luca","32439211"],"journal":"Lung Cancer","authors":["Di Noia, Vincenzo","D'Aveni, Alessandro","Squadroni, Michela","Beretta, Giordano Domenico","Ceresoli, Giovanni Luca"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439211","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.lungcan.2020.05.006","topics":["Case Report"],"weight":1,"_version_":1667523504783753216,"score":48.15703},{"pmid":32455475,"title":"COVID-19 in a melanoma patient under treatment with checkpoint-inhibition.","text":["COVID-19 in a melanoma patient under treatment with checkpoint-inhibition.","SARS-CoV-2 poses new challenges in all aspects of healthcare. Patients with preexisting cardio-vascular conditions are at higher risk of developing severe symptoms and worse outcome. Data also suggest that cancer patients are particularly vulnerable, but differences between tumor entities and cancer treatments may exist. Little is known how cancer treatment engaging immune checkpoints affects the course of COVID-19.","J Eur Acad Dermatol Venereol","Schmidle, P","Biedermann, T","Posch, C","32455475"],"abstract":["SARS-CoV-2 poses new challenges in all aspects of healthcare. Patients with preexisting cardio-vascular conditions are at higher risk of developing severe symptoms and worse outcome. Data also suggest that cancer patients are particularly vulnerable, but differences between tumor entities and cancer treatments may exist. Little is known how cancer treatment engaging immune checkpoints affects the course of COVID-19."],"journal":"J Eur Acad Dermatol Venereol","authors":["Schmidle, P","Biedermann, T","Posch, C"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32455475","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jdv.16661","topics":["Case Report"],"weight":1,"_version_":1667983494576340994,"score":42.35933}]}